Ann: Two-Year Results of Phase 1 SR-aGvHD Trial Presented at ISCT, page-50

"That said, I think the company is years away from commercialising anything, especially given the CEO's comments that GVHD would be the first cab off the rank and they have been touting that the phase 2 GVHD trial was going to start for years". Again, I am an MSB shareholder, but come on, 19 years for MSB to get where it has from its IPO. This is never a fast process for any aspect of bio-tech, let alone stem cells. But CYP does not have to compete with MSB....it only has to hang on to its coat tails.

Could not agree more regards GVHD and Ross' spin. Why I did not buy CYP far higher. Like so many executive teams, full of talk when things going well - Ross has in his defense bought plenty of stock though, so believed his own spin. I am not really on CYP for any anticipated future approvals in GvHD, at least whilst it remains the business entity it is. I am recently in it for its phase III, all Australian, Government funded, University sponsored, knee OA trial using Mesenchymal stem cells, which, to the ignorance of the majority of investors, there has been a very large and successful phase III trial in already in Korea....and its very likely acquisition status when/should MSB be approved for GvHD.

Absolutely MSB will first "off the rank" and well off into the distance commercially (I hope) before CYP even starts its phase III in srGvHD. The COVID tangent was a poor strategic waste of money. This is not. GvHD a nice little each way takeover bet for CYP, that's its just shown 60%, 2-year survival rates in using Mesenchymal stem cells, that resolves many questions that have come to light on the potency, scalability and variability questions raised by the FDA in the past with regard to MSB and other MSc approaches using multiple donors. MSB can get what, about 500 doses per bone marrow donation? Inherently limited scalability and consistency in MSC manufacturing are inefficiencies that have not gone away. Cynata only has to hang on to MSB's coat tails, which it has done here reporting 2-year, 60% survival in srGHVD, to be a very tempting take over target should MSB be approved in srGvHD - and I think it soon will be.

The years of vitriol on here with Sector putting CYP vs MSB, has blinded people to the synergies/complementarity between MSB and CYP. Sumitomo looked at CYP for $200 million in 2019 well ahead of MSB's likely success and any stage three trial by CYP. If MSB has success, no way CYP will not be bought out if it remains below $100 million mkt cap, particularly given its early stage replication of MSB's success as shown here in GVHD.